Bio-Path Holdings, Inc. is on the Cruelty Free Investing use of animals list because they exploit animals for conducting pre-clinical trials of their drugs and therapies.
Peter Nielsen, President and Chief Executive Officer of Bio-Path said that “We are honored to collaborate with Dr. Fleming. His experience working with pancreatic xenografts makes him uniquely qualified to lead this study. We look forward to assessing whether Bio-Path’s drug candidates work in this ex vivo model before potentially moving into animal studies.”(Page 5)
Bio-Path Holdings, Inc. is a clinical stage biotechnology company, which focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. Bio-Path Holdings was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Maria Tari in May 10, 2007 and is headquartered in Bellaire, TX. [Source: MarketWatch]